28 results on '"Rocci, Alberto"'
Search Results
2. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
- Author
-
Jackson, Graham H., Pawlyn, Charlotte, Cairns, David A., de Tute, Ruth M., Hockaday, Anna, Collett, Corinne, Jones, John R., Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D., Karunanithi, Kamaraj, Lindsay, Jindriska, Rocci, Alberto, Snowden, John A., Jenner, Matthew W., Cook, Gordon, Russell, Nigel H., Drayson, Mark T., Gregory, Walter M., Kaiser, Martin F., Owen, Roger G., Davies, Faith E., and Morgan, Gareth J.
- Subjects
Cyclophosphamide -- Dosage and administration ,Dexamethasone -- Dosage and administration ,Multiple myeloma -- Drug therapy ,Chemotherapy -- Methods ,Carfilzomib -- Dosage and administration ,Cancer -- Chemotherapy ,Biological sciences - Abstract
Background Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome inhibitors, making it more amenable to combination therapy. Methods and findings The Myeloma XI+ trial recruited patients from 88 sites across the UK between 5 December 2013 and 20 April 2016. Patients with newly diagnosed multiple myeloma eligible for transplantation were randomly assigned to receive the combination carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) or a triplet of lenalidomide, dexamethasone, and cyclophosphamide (Rdc) or thalidomide, dexamethasone, and cyclophosphamide (Tdc). All patients were planned to receive an autologous stem cell transplantation (ASCT) prior to a randomisation between lenalidomide maintenance and observation. Eligible patients were aged over 18 years and had symptomatic myeloma. The co-primary endpoints for the study were progression-free survival (PFS) and overall survival (OS) for KRdc versus the Tdc/Rdc control group by intention to treat. PFS, response, and safety outcomes are reported following a planned interim analysis. The trial is registered (ISRCTN49407852) and has completed recruitment. In total, 1,056 patients (median age 61 years, range 33 to 75, 39.1% female) underwent induction randomisation to KRdc (n = 526) or control (Tdc/Rdc, n = 530). After a median follow-up of 34.5 months, KRdc was associated with a significantly longer PFS than the triplet control group (hazard ratio 0.63, 95% CI 0.51-0.76). The median PFS for patients receiving KRdc is not yet estimable, versus 36.2 months for the triplet control group (p < 0.001). Improved PFS was consistent across subgroups of patients including those with genetically high-risk disease. At the end of induction, the percentage of patients achieving at least a very good partial response was 82.3% in the KRdc group versus 58.9% in the control group (odds ratio 4.35, 95% CI 3.19-5.94, p < 0.001). Minimal residual disease negativity (cutoff 4 x 10.sup.-5 bone marrow leucocytes) was achieved in 55% of patients tested in the KRdc group at the end of induction, increasing to 75% of those tested after ASCT. The most common adverse events were haematological, with a low incidence of cardiac events. The trial continues to follow up patients to the co-primary endpoint of OS and for planned long-term follow-up analysis. Limitations of the study include a lack of blinding to treatment regimen and that the triplet control regimen did not include a proteasome inhibitor for all patients, which would be considered a current standard of care in many parts of the world. Conclusions The KRdc combination was well tolerated and was associated with both an increased percentage of patients achieving at least a very good partial response and a significant PFS benefit compared to immunomodulatory-agent-based triplet therapy. Trial registration ClinicalTrials.gov ISRCTN49407852., Author(s): Graham H. Jackson 1,*, Charlotte Pawlyn 2,3, David A. Cairns 4, Ruth M. de Tute 5, Anna Hockaday 4, Corinne Collett 4, John R. Jones 6, Bhuvan Kishore 7, [...]
- Published
- 2021
- Full Text
- View/download PDF
3. RWD-derived response in multiple myeloma.
- Author
-
Xu, Tao, Roose, James, Williamson, Mellissa, Sawas, Ahmed, Hong, Wan-Jen, Jin, Huan, Maignan, Kathleen, Rocci, Alberto, Yousefi, Kasra, Kumar, Shaji, and Tyanova, Stefka
- Subjects
MULTIPLE myeloma ,CLINICAL trials ,MONOCLONAL antibodies ,OVERALL survival ,ODDS ratio - Abstract
Real-world data (RWD) are important for understanding the treatment course and response patterns of patients with multiple myeloma. This exploratory pilot study establishes a way to reliably assess response from incomplete laboratory measurements captured in RWD. A rule-based algorithm, adapted from International Myeloma Working Group response criteria, was used to derive response using RWD. This derived response (dR) algorithm was assessed using data from the phase III BELLINI trial, comparing the number of responders and non-responders assigned by independent review committee (IRC) versus the dR algorithm. To simulate a real-world scenario with missing data, a sensitivity analysis was conducted whereby available laboratory measurements in the dataset were artificially reduced. Associations between dR and overall survival were evaluated at 1) individual level and 2) treatment level in a real-world patient cohort obtained from a nationwide electronic health record-derived de-identified database. The algorithm's assignment of responders was highly concordant with that of the IRC (Cohen's Kappa 0.83) using the BELLINI data. The dR replicated the differences in overall response rate between the intervention and placebo arms reported in the trial (odds ratio 2.1 vs. 2.3 for IRC vs. dR assessment, respectively). Simulation of missing data in the sensitivity analysis (-50% of available laboratory measurements and -75% of urine monoclonal protein measurements) resulted in a minor reduction in the algorithm's accuracy (Cohen's Kappa 0.75). In the RWD cohort, dR was significantly associated with overall survival at all landmark times (hazard ratios 0.80–0.81, p<0.001) at the individual level, while the overall association was R
2 = 0.67 (p<0.001) at the treatment level. This exploratory pilot study demonstrates the feasibility of deriving accurate response from RWD. With further confirmation in independent cohorts, the dR has the potential to be used as an endpoint in real-world studies and as a comparator in single-arm clinical trials. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma
- Author
-
Bolomsky, Arnold, Hübl, Wolfgang, Spada, Stefano, Müldür, Ercan, Schlangen, Karin, Heintel, Daniel, Rocci, Alberto, Weimann, Adalbert, Fritz, Veronique, Willheim, Martin, Zojer, Niklas, Palumbo, Antonio, and Ludwig, Heinz
- Published
- 2017
- Full Text
- View/download PDF
5. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients
- Author
-
Rocci, Alberto, Gambella, Manuela, Aschero, Simona, Baldi, Ileana, Trusolino, Livio, Cavallo, Federica, Gay, Francesca, Larocca, Alessandra, Magarotto, Valeria, Omedè, Paola, Isaia, Gianluca, Bertotti, Andrea, Liberati, Anna M., Catalano, Lucio, De Rosa, Luca, Musto, Pellegrino, Vallone, Roberto, Falcone, Antonietta, Drandi, Daniela, Ladetto, Marco, Comoglio, Paolo M., Boccadoro, Mario, and Palumbo, Antonio
- Published
- 2014
- Full Text
- View/download PDF
6. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
- Author
-
Heintel, Daniel, Rocci, Alberto, Ludwig, Heinz, Bolomsky, Arnold, Caltagirone, Simona, Schreder, Martin, Pfeifer, Sabine, Gisslinger, Heinz, Zojer, Niklas, Jäger, Ulrich, and Palumbo, Antonio
- Published
- 2013
- Full Text
- View/download PDF
7. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations
- Author
-
Agnelli, Luca, Storti, Paola, Todoerti, Katia, Sammarelli, Gabriella, Dalla Palma, Benedetta, Bolzoni, Marina, Rocci, Alberto, Piazza, Francesco, Semenzato, Gianpietro, Palumbo, Antonio, Neri, Antonino, and Giuliani, Nicola
- Published
- 2011
- Full Text
- View/download PDF
8. Compound heterozygosity for two new TERT mutations in a patient with aplastic anemia
- Author
-
Aspesi, Anna, Vallero, Stefano, Rocci, Alberto, Pavesi, Elisa, Lanciotti, Marina, Ramenghi, Ugo, and Dianzani, Irma
- Published
- 2010
- Full Text
- View/download PDF
9. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
- Author
-
Ladetto, Marco, Vallet, Sonia, Trojan, Andreas, Dell'Aquila, Maria, Monitillo, Luigia, Rosato, Rosalba, Santo, Loredana, Drandi, Daniela, Bertola, Alessandra, Falco, Patrizia, Cavallo, Federica, Ricca, Irene, De Marco, Federica, Mantoan, Barbara, Bode-Lesniewska, Beata, Pagliano, Gloria, Francese, Roberto, Rocci, Alberto, Astolfi, Monica, Compagno, Mara, Mariani, Sara, Godio, Laura, Marino, Lydia, Ruggeri, Marina, Omedè, Paola, Palumbo, Antonio, and Boccadoro, Mario
- Published
- 2005
- Full Text
- View/download PDF
10. Analysis of Telomeres in Peripheral Blood Cells From Patients With Bone Marrow Failure1
- Author
-
Pavesi, Elisa, Avondo, Federica, Aspesi, Anna, Quarello, Paola, Rocci, Alberto, Vimercati, Chiara, Pigullo, Simona, Dufour, Carlo, Ramenghi, Ugo, and Dianzani, Irma
- Published
- 2009
- Full Text
- View/download PDF
11. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
- Author
-
Bonanno Giuseppina, Mariotti Andrea, Procoli Annabella, Folgiero Valentina, Natale Daniela, De Rosa Luca, Majolino Ignazio, Novarese Linda, Rocci Alberto, Gambella Manuela, Ciciarello Marilena, Scambia Giovanni, Palumbo Antonio, Locatelli Franco, De Cristofaro Raimondo, and Rutella Sergio
- Subjects
Medicine - Abstract
Abstract Background Multiple myeloma (MM) is a plasma cell malignancy with a multifaceted immune dysfunction. Indoleamine 2,3-dioxygenase 1 (IDO1) degrades tryptophan into kynurenine (KYN), which inhibits effector T cells and promote regulatory T-cell (Treg) differentiation. It is presently unknown whether MM cells express IDO1 and whether IDO1 activity correlates with immune system impairment. Methods We investigated IDO1 expression in 25 consecutive patients with symptomatic MM and in 7 patients with either monoclonal gammopathy of unknown significance (MGUS; n=3) or smoldering MM (SMM; n=4). IDO1-driven tryptophan breakdown was correlated with the release of hepatocyte growth factor (HGF) and with the frequency of Treg cells and NY-ESO-1-specific CD8+ T cells. Results KYN was increased in 75% of patients with symptomatic MM and correlated with the expansion of CD4+CD25+FoxP3+ Treg cells and the contraction of NY-ESO-1-specific CD8+ T cells. In vitro, primary MM cells promoted the differentiation of allogeneic CD4+ T cells into bona fide CD4+CD25hiFoxP3hi Treg cells and suppressed IFN-γ/IL-2 secretion, while preserving IL-4 and IL-10 production. Both Treg expansion and inhibition of Th1 differentiation by MM cells were reverted, at least in part, by d,l-1-methyl-tryptophan, a chemical inhibitor of IDO. Notably, HGF levels were higher within the BM microenvironment of patients with IDO+ myeloma disease compared with patients having IDO- MM. Mechanistically, the antagonism of MET receptor for HGF with SU11274, a MET inhibitor, prevented HGF-induced AKT phosphorylation in MM cells and translated into reduced IDO protein levels and functional activity. Conclusions These data suggest that IDO1 expression may contribute to immune suppression in patients with MM and possibly other HGF-producing cancers.
- Published
- 2012
- Full Text
- View/download PDF
12. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
- Author
-
Dimopoulos, Meletios A., Jakubowiak, Andrzej J., McCarthy, Philip L., Orlowski, Robert Z., Attal, Michel, Bladé, Joan, Goldschmidt, Hartmut, Weisel, Katja C., Ramasamy, Karthik, Zweegman, Sonja, Spencer, Andrew, Huang, Jeffrey S. Y., Lu, Jin, Sunami, Kazutaka, Iida, Shinsuke, Chng, Wee-Joo, Holstein, Sarah A., Rocci, Alberto, Skacel, Tomas, and Labotka, Richard
- Subjects
MULTIPLE myeloma diagnosis ,CYTOREDUCTIVE surgery ,MULTIPLE myeloma treatment ,BORTEZOMIB ,STEM cell transplantation ,DISEASE progression - Abstract
The evolving paradigm of continuous therapy and maintenance treatment approaches in multiple myeloma (MM) offers prolonged disease control and improved outcomes compared to traditional fixed-duration approaches. Potential benefits of long-term strategies include sustained control of disease symptoms, as well as continued cytoreduction and clonal control, leading to unmeasurable residual disease and the possibility of transforming MM into a chronic or functionally curable condition. "Continuous therapy" commonly refers to administering a doublet or triplet regimen until disease progression, whereas maintenance approaches typically involve single-agent or doublet treatment following more intensive prior therapy with autologous stem cell transplant (ASCT) or doublet, triplet, or even quadruplet induction therapy. However, the requirements for agents and regimens within these contexts are similar: treatments must be tolerable for a prolonged period of time, should not be associated with cumulative or chronic toxicity, should not adversely affect patients' quality of life, should ideally be convenient with a minimal treatment burden for patients, and should not impact the feasibility or efficacy of subsequent treatment at relapse. Multiple agents have been and are being investigated as long-term options in the treatment of newly diagnosed MM (NDMM), including the immunomodulatory drugs lenalidomide and thalidomide, the proteasome inhibitors bortezomib, carfilzomib, and ixazomib, and the monoclonal antibodies daratumumab, elotuzumab, and isatuximab. Here we review the latest results with long-term therapy approaches in three different settings in NDMM: (1) maintenance treatment post ASCT; (2) continuous frontline therapy in nontransplant patients; (3) maintenance treatment post-frontline therapy in the nontransplant setting. We also discuss evidence from key phase 3 trials. Our review demonstrates how the paradigm of long-term treatment is increasingly well-established across NDMM treatment settings, potentially resulting in further improvements in patient outcomes, and highlights key clinical issues that will need to be addressed in order to provide optimal benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
- Author
-
Bastidas, Adriana, de la Serna, Javier, El Idrissi, Mohamed, Oostvogels, Lidia, Quittet, Philippe, López-Jiménez, Javier, Vural, Filiz, Pohlreich, David, Zuckerman, Tsila, Issa, Nicolas C., Gaidano, Gianluca, Lee, Je-Jung, Abhyankar, Sunil, Solano, Carlos, Perez de Oteyza, Jaime, Satlin, Michael J., Schwartz, Stefan, Campins, Magda, Rocci, Alberto, and Vallejo Llamas, Carlos
- Subjects
HERPES zoster vaccines ,HERPES zoster ,HEMATOPOIETIC stem cell transplantation ,RECOMBINANT drugs ,CLINICAL trials ,HERPES zoster prevention ,RESEARCH ,IMMUNOCOMPROMISED patients ,NEURALGIA ,RESEARCH methodology ,DISEASE incidence ,IMMUNOMODULATORS ,EVALUATION research ,MEDICAL cooperation ,INTRAMUSCULAR injections ,AUTOGRAFTS ,COMPARATIVE studies ,RANDOMIZED controlled trials ,BLIND experiment ,HOSPITAL care ,PROPORTIONAL hazards models ,LONGITUDINAL method - Abstract
Importance: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster.Objective: To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients.Design, Setting, and Participants: Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT.Interventions: Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n = 922) or placebo (n = 924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter.Main Outcomes and Measures: The primary end point was occurrence of confirmed herpes zoster cases.Results: Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P < .001), equivalent to 68.2% vaccine efficacy. Of 8 secondary end points, 3 showed significant reductions in incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR, 0.1; 95% CI, 0.00-0.78; P = .02) and of other prespecified herpes zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22; 95% CI, 0.04-0.81; P = .02) and in duration of severe worst herpes zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days; hazard ratio, 0.62; 95% CI, 0.42-0.89; P = .01). Five secondary objectives were descriptive. Injection site reactions were recorded in 86% of vaccine and 10% of placebo recipients, of which pain was the most common, occurring in 84% of vaccine recipients (grade 3: 11%). Unsolicited and serious adverse events, potentially immune-mediated diseases, and underlying disease relapses were similar between groups at all time points.Conclusions and Relevance: Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months.Trial Registration: ClinicalTrials.gov Identifier: NCT01610414. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
14. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
- Author
-
Gambella, Manuela, Omedé, Paola, Spada, Stefano, Muccio, Vittorio Emanuele, Gilestro, Milena, Saraci, Elona, Grammatico, Sara, Larocca, Alessandra, Conticello, Concetta, Bernardini, Annalisa, Gamberi, Barbara, Troia, Rossella, Liberati, Anna Marina, Offidani, Massimo, Rocci, Alberto, Palumbo, Antonio, Cavo, Michele, Sonneveld, Pieter, Boccadoro, Mario, and Oliva, Stefania
- Subjects
POLYMERASE chain reaction ,REVERSE transcriptase polymerase chain reaction ,FLOW cytometry ,OLIGONUCLEOTIDE synthesis ,ONCOLOGY ,MULTIPLE myeloma ,PROGRESSION-free survival - Abstract
Background: Minimal residual disease (MRD) is one of the most relevant prognostic factors in patients with multiple myeloma (MM); however, the impact of maintenance therapy on MRD levels remains unclear. Among patients with newly diagnosed MM (NDMM) who received lenalidomide maintenance until they developed disease progression, the role of MRD status as a predictor of progression-free survival (PFS) was evaluated by multiparameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) analysis.Methods: Seventy-three patients with NDMM enrolled in the RV-MM-EMN-441 (clinical trials.gov identifier, NCT01091831) and RV-MM-COOP-0556 (clinicaltrials.gov identifier, NCT01208766; European Myeloma Network EMN02/HO95 MM Trial) phase 3 trials who achieved at least a very good partial response after intensification/consolidation were included. The median patient age was 57 years (interquartile range, 53-61 years), and all patients received lenalidomide maintenance until they developed progression. MRD was evaluated on bone marrow after intensification/consolidation, after 6 courses of maintenance, and every 6 months thereafter until clinical relapse using both ASO-RQ-PCR (sensitivity, 10-5 ) and MFC (sensitivity, from 10-4 to 10-5 ).Results: After intensification/consolidation, 33 of 72 patients (46%) achieved a molecular complete response (m-CR), and 44 of 70 (63%) achieved a flow complete response (flow-CR). Almost 27% of patients who were MRD-positive after consolidation became MRD-negative during maintenance. After a median follow-up of 38 months, PFS was prolonged in patients who achieved negative MRD status during maintenance according to results from both ASO-RQ-PCR analysis (hazard ratio, 0.29; 95% confidence interval, 0.14-0.62; P = .0013) and MFC (hazard ratio, 0.19; 95% confidence interval, 0.09-0.41; P < .001). The impact of negative MRD status on PFS was similar in all subgroups (ASCT and no-ASCT; International Staging System stages I, II, and III; high-risk and standard-risk cytogenetics), and the two techniques were highly correlated.Conclusions: MRD status is a stronger predictor of PFS than standard risk factors, and lenalidomide maintenance further increases the rate of negative MRD results. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
15. Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations.
- Author
-
Swan, Dawn, Rocci, Alberto, Bradbury, Charlotte, and Thachil, Jecko
- Subjects
- *
MULTIPLE myeloma , *THROMBOEMBOLISM , *IMMUNOMODULATORS , *ANTICOAGULANTS , *THROMBOSIS - Abstract
Summary: Multiple myeloma is associated with a significant risk of venous thromboembolism (VTE), causing substantial levels of morbidity and mortality. The thrombogenicity of myeloma is multifactorial, with disease‐ and treatment‐related factors playing important roles. Immunomodulatory drugs (IMiDs) and high‐dose dexamethasone, in particular, are known to enhance the thrombotic potential of myeloma. For this reason, assessment of the VTE risk has long been advocated prior to treatment initiation in patients with myeloma requiring IMiD‐based regimens. However, despite routine use of thromboprophylaxis, these patients can still develop VTE and its sequelae. The optimum choice and dose of thromboprophylactic drug is not entirely clear, and with this, there is growing interest regarding use of the direct oral anticoagulants in this setting. In this review we discuss the pathogenesis of thrombosis in multiple myeloma, its relation to some of the commonly used chemotherapeutic regimens, current risk stratification and the evidence supporting the different anticoagulants used as thromboprophylaxis. We propose an amended risk stratification, and consider management of challenging patients, including those with renal impairment and recurrent thrombosis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
- Author
-
Richardson, Paul G., Amatangelo, Michael, Berenson, James R., Cerchione, Claudio, Dimopoulos, Meletios A., Toftmann Hansen, Charlotte, Hwang, Soo Jeong, Koo, Phillip, Kuroda, Junya, Oriol, Albert, Orlowski, Robert Z., Quach, Hang, Raab, Marc S., Rocci, Alberto, Wang, Yue, White, Darrell, Yu, Brian, Zhou, Zehua, and Katz, Jessica
- Published
- 2023
- Full Text
- View/download PDF
17. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
- Author
-
Gambella, Manuela, Palumbo, Antonio, and Rocci, Alberto
- Abstract
The interaction between neoplastic cells and the microenvironment is critical in several cancers and plays a central role in multiple myeloma. Microenvironmental stimuli support plasma cell proliferation, survival, motility and can determine drug resistance. The network between plasma cells and surrounding cells is also responsible for increasing angiogenesis, unbalancing bone formation and bony lesions. The MET/HGF pathway is a key player in this interaction and has been found to be abnormally active in both malignant plasma cells and surrounding cells. Patients with abnormal MET and/or HGF levels usually have a poor outcome even when treated with novel drugs. This review addresses the role of MET/HGF in the pathogenesis of myeloma and describes the role of MET/HGF signaling as a prognostic factor. The different techniques to detect MET/HGF abnormalities are examined and a description of compounds targeting MET/HGF is also provided. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. The potential of miRNAs as biomarkers for multiple myeloma.
- Author
-
Rocci, Alberto, Hofmeister, Craig C, and Pichiorri, Flavia
- Abstract
Since the discovery of the link between miRNA and cancer, miRNAs have been investigated in virtually all tumors. Their ability to add a novel level of gene regulation and to target genes apparently not linked to each other has greatly intrigued researchers and physicians alike. In this review, the role of miRNAs in multiple myeloma (MM) is summarized, with particular attention to their potential as biomarkers. The promising role of circulating miRNAs in diagnosis and risk stratification is also discussed, as well as preliminary results of miRNA-based therapeutic approaches. Finally, the critical issues in miRNA analysis in MM and ongoing strategies to solve them are discussed. The ability to standardize miRNA analysis procedures will permit the inclusion of miRNA evaluation alongside available stratification tools, paving the way for personalized medicine in MM. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
19. Characterization of multiple myeloma vesicles by label-free relative quantitation.
- Author
-
Harshman, Sean W., Canella, Alessandro, Ciarlariello, Paul D., Rocci, Alberto, Agarwal, Kitty, Smith, Emily M., Talabere, Tiffany, Efebera, Yvonne A., Hofmeister, Craig C., Benson, Don M., Paulaitis, Michael E., Freitas, Michael A., and Pichiorri, Flavia
- Published
- 2013
- Full Text
- View/download PDF
20. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
- Author
-
Engelhardt, Monika, Udi, Josefina, Kleber, Martina, Spencer, Andrew, Rocci, Alberto, Knop, Stefan, Bruno, Benedetto, Bringhen, Sara, Pérez-Simón, José A., Zweegman, Sonja, Driessen, Christoph, Patriarca, Francesca, Gramatzki, Martin, Terpos, Evangelos, Sezer, Orhan, Kropff, Martin, Straka, Christian, Johnsen, Hans E., Waage, Anders, and Boegsted, Martin
- Subjects
MULTIPLE myeloma ,CYTOGENETICS ,DIAGNOSTIC use of fluorescence in situ hybridization ,PHYSIOLOGICAL effects of chemotherapy ,STEM cell transplantation ,DEXAMETHASONE - Abstract
Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. Conventional cytogenetics and fluorescence in situ hybridization are routinely assessed in MM, and when combined with ISS stage may attain an even better predictive potential. In order to achieve even more effective and individualized therapies, one crucial goal is the identification of genes and gene combinations that predict for response or resistance to chemotherapy. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in MM. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
21. Long-term lymphoma survivors following high-dose chemotherapy and autograft: Evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir
- Author
-
Rocci, Alberto, Ricca, Irene, Dellacasa, Chiara, Longoni, Paolo, Compagno, Mara, Francese, Roberto, Lobetti Bodoni, Chiara, Manzini, Paola, Caracciolo, Daniele, Boccadoro, Mario, Ferrero, Dario, Ladetto, Marco, Carlo-Stella, Carmelo, and Tarella, Corrado
- Subjects
- *
LYMPHOMAS , *DRUG therapy , *AUTOGRAFTS , *TELOMERES , *PATIENTS - Abstract
Objective: To investigate telomere length (TL) and hematopoietic progenitors in long-term survivors after high-dose chemotherapy and peripheral blood stem cell (PBSC) autograft. Methods: Peripheral blood (PB) and bone marrow (BM) samples were obtained from 31 subjects in continuous complete remission from a high-risk lymphoma, at a median of 5.8 years (range: 1–11 years) since autograft. Most of them were grafted with large PBSC quantities (median CD34+ve cells/kg: 7 × 106). TL was determined by Southern blot analysis, BM progenitors by in vitro long-term culture-initiating cells (LTC-IC) and colony assays. Results: TL of PB granulocytes was significantly shortened in autografted subjects compared with age-matched healthy subjects; a similar finding was observed in BM. The median TL reduction in granulocytes from autografted subjects compared with age-matched controls (ΔTelShortening) was then assessed according to time interval since autograft. Three subject subgroups were identified—at 1 to <3 years, 3 to <6 years, and 6 to 11 years since autograft—and their telomere loss was the same, with ΔTelShortening of 1132, 1379, and 1214 bp in the three subgroups, respectively. The longitudinal assessment of TL in five representative patients followed for up to 40 months since autograft confirmed that telomere shortening occurring during exposure to chemotherapy as well as postautograft is persistent at long term. BM LTC-IC and multipotent and committed progenitors were assessed in subjects at >3 years after autograft and found to be markedly reduced compared with normal controls. Conclusion: High-dose chemotherapy and PBSC autograft may result in myelopoietic cell abnormalities that appear to be irreversible. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
22. High IKAROS Expression in Bone Marrow Environmental, But Not in Myeloma Cells Predicts for Survival with Lenalidomide-Dexamethasone Therapy in Myeloma.
- Author
-
Bolomsky, Arnold, Hübl, Wolfgang, Spada, Stefano, Müldür, Ercan, Schlangen, Karin, Heintel, Daniel, Rocci, Alberto, Weißmann, Adalbert, Fritz, Veronique, Wilheim, Martin, Zojer, Niklas, Palumbo, Antonio, and Ludwig, Heinz
- Published
- 2017
- Full Text
- View/download PDF
23. Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development.
- Author
-
Pichiorri, Flavia, Suh, Sung-Suk, Rocci, Alberto, De Luca, Luciana, Taccioli, Cristian, Santhanam, Ramasamy, Zhou, Wenchao, Benson, Don M., Hofmainster, Craig, Alder, Hansjuerg, Garofalo, Michela, Di Leva, Gianpiero, Volinia, Stefano, Lin, Huey-Jen, Perrotti, Danilo, Kuehl, Michael, Aqeilan, Rami I., Palumbo, Antonio, and Croce, Carlo M.
- Subjects
- *
MICRORNA , *DOWNREGULATION , *MULTIPLE myeloma - Published
- 2022
- Full Text
- View/download PDF
24. Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
- Author
-
Pichiorri, Flavia, Suh, Sung-Suk, Rocci, Alberto, De Luca, Luciana, Taccioli, Cristian, Santhanam, Ramasamy, Zhou, Wenchao, Benson, Don M., Hofmainster, Craig, Alder, Hansjuerg, Garofalo, Michela, Di Leva, Gianpiero, Volinia, Stefano, Lin, Huey-Jen, Perrotti, Danilo, Kuehl, Michael, Aqeilan, Rami I., Palumbo, Antonio, and Croce, Carlo M.
- Subjects
- *
GENETIC regulation , *NON-coding RNA , *MULTIPLE myeloma , *P53 antioncogene , *B cell lymphoma , *ENZYME inhibitors , *GENE expression , *GENE targeting , *GENETIC mutation - Abstract
Summary: In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is rarely detected at diagnosis. Using small-molecule inhibitors of MDM2, we provide evidence that miR-192, 194, and 215, which are downregulated in a subset of newly diagnosed MMs, can be transcriptionally activated by p53 and then modulate MDM2 expression. Furthermore, ectopic re-expression of these miRNAs in MM cells increases the therapeutic action of MDM2 inhibitors in vitro and in vivo by enhancing their p53-activating effects. In addition, miR-192 and 215 target the IGF pathway, preventing enhanced migration of plasma cells into bone marrow. The results suggest that these miRNAs are positive regulators of p53 and that their downregulation plays a key role in MM development. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
25. Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development.
- Author
-
Pichiorri, Flavia, Suh, Sung-Suk, Rocci, Alberto, De Luca, Luciana, Taccioli, Cristian, Santhanam, Ramasamy, Zhou, Wenchao, Benson, Don M., Hofmainster, Craig, Alder, Hansjuerg, Garofalo, Michela, Di Leva, Gianpiero, Volinia, Stefano, Lin, Huey-Jen, Perrotti, Danilo, Kuehl, Michael, Aqeilan, Rami I., Palumbo, Antonio, and Croce, Carlo M.
- Subjects
- *
DOWNREGULATION , *P53 antioncogene , *MICRORNA , *MULTIPLE myeloma , *PROTEIN kinase B - Published
- 2016
- Full Text
- View/download PDF
26. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors.
- Author
-
Tornatore, Laura, Sandomenico, Annamaria, Raimondo, Domenico, Low, Caroline, Rocci, Alberto, Tralau-Stewart, Cathy, Capece, Daria, D’Andrea, Daniel, Bua, Marco, Boyle, Eileen, van Duin, Mark, Zoppoli, Pietro, Jaxa-Chamiec, Albert, Thotakura, Anil K., Dyson, Julian, Walker, Brian A., Leonardi, Antonio, Chambery, Angela, Driessen, Christoph, and Sonneveld, Pieter
- Subjects
- *
NF-kappa B , *ENZYME inhibitors , *CELLULAR signal transduction , *MULTIPLE myeloma , *TARGETED drug delivery , *DRUG development , *IN vitro studies , *PATIENTS - Abstract
Summary Constitutive NF-κB signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-κB-targeting strategies lack cancer cell specificity. Here, we identify the interaction between the NF-κB-regulated antiapoptotic factor GADD45β and the JNK kinase MKK7 as a therapeutic target in MM. Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45β/MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells. DTP3 has similar anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity in vitro. Notably, DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective doses. Hence, cancer-selective targeting of the NF-κB pathway is possible and, at least for myeloma patients, promises a profound benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations
- Author
-
Ladetto, Marco, Mantoan, Barbara, De Marco, Federica, Drandi, Daniela, Aguzzi, Chiara, Astolfi, Monica, Vallet, Sonia, Ricca, Irene, Aquila, Maria Dell', Pagliano, Gloria, Monitillo, Luigia, Pollio, Berardino, Santo, Loredana, Cristiano, Carmen, Rocci, Alberto, Francese, Roberto, Bodoni, Chiara Lobetti, Borchiellini, Alessandra, Schinco, Piercarla, and Boccadoro, Mario
- Subjects
- *
LYMPHOMAS , *NUCLEIC acids , *CELLS , *RETICULOENDOTHELIAL granulomas - Abstract
Objective: Nonlymphoma-associated bcl-2/IgH rearrangements (NLABRs) are frequently amplified by PCR in blood of lymphoma-free subjects (LFS), but the temporal kinetics and phenotypic nature of NLABR-positive cells are unknown. To address these issues we prospectively monitored a panel of NLABR-positive LFS. Methods: LFS have been studied by nested PCR, real-time PCR, and DNA sequencing. Cell selection studies were also performed to define the nature of NLABR-bearing clones. Results: Of 125 donors, 16 (12.8%) were found to be bcl-2/IgH positive and were monitored at least every 6 months for a median time of 22 months (range 6–50). In half of the subjects the same NLABR detected initially was again reamplified at follow-up thrice or more. In 5, the same NLABR was constantly amplified in every follow-up sample. With a median follow-up of 22 months (range 9–50), no stable disappearance of a recurrent clone has been so far recorded. Real-time PCR indicated that persistent NLABR-positive clones are stable over time in the same subject. Cell separation studies indicate that NLABRs belong to CD19+, CD5−, CD23−, CD10+/− cells. Conclusions: Our results indicate that NLABR-positive clones are persistent populations phenotypically related to follicular lymphoma (FL). This suggests the existence of a FL-related clonal expansion of undetermined significance, which might be either a premalignant or a nonmalignant counterpart of FL. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
28. Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone
- Author
-
Ladetto, Marco, Mantoan, Barbara, Ricca, Irene, Astolfi, Monica, Drandi, Daniela, Compagno, Mara, Vallet, Sonia, dell'Aquila, Maria, Alfarano, Alda, Rossatto, Paola, Rocci, Alberto, Vitolo, Umberto, Corradini, Paolo, Boccadoro, Mario, and Tarella, Corrado
- Subjects
- *
POLYMERASE chain reaction , *DISEASE relapse , *LYMPHOMAS , *PATIENTS - Abstract
Objective. The aim of this study was to evaluate whether reappearance of polymerase chain reaction (PCR) positivity for the Bcl-2/IgH translocation following a phase of molecular remission in autografted follicular lymphoma (FL) patients is always associated with reappearance of the original neoplastic clone.Patients and methods. The molecular follow-up of 119 autografted Bcl-2/IgH positive patients was evaluated by nested PCR. In case of molecular recurrence, direct sequencing of involved rearrangements has been performed both at diagnosis and at the time of recurrence. The two sequences then were compared in terms of breakpoints, N insertions, and JH usage.Results. Seventy-five patients achieving molecular remission were identified in our patient sample (63%). Of these patients, eight (10.6%) experienced molecular recurrence. Direct sequencing of the Bcl-2/IgH translocation performed at diagnosis and recurrence showed identical rearrangements in six subjects and unrelated rearrangements in two. As opposed to most true molecular relapses, unrelated rearrangements always occurred several years after transplantation. To date, the two subjects carrying unrelated rearrangements show no signs of active lymphoproliferative disease.Conclusions. This report is the first evidence that Bcl-2/IgH rearrangements unrelated to the original tumor clone can lead to false-positive results during the molecular follow-up of autografted FL patients. Based on these results, we recommend confirmation by direct sequencing, at least for patients experiencing molecular relapse 2 or more years after the end of treatment. This will be particularly important for patients enrolled in clinical trials that schedule additional treatment in case of molecular evidence of persistent disease activity. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.